Elevance Health Inc. ($ELV) Stock Forecast: Up 6.0% Today

What is Elevance Health Inc.?

Elevance Health (ELV) Analyst Assessment

Why is Elevance Health Inc. going up?

ELV stock is up 6.0% on Dec 11, 2025 20:42

• Elevance Health (ELV) has shown a strong bullish movement in the market recently.
• The appointment of Amy W. Schulman as an independent director is being viewed positively, enhancing the company's governance and oversight capabilities.
• Analysts have adjusted the price target for ELV to $340 from $297, maintaining a Neutral rating, indicating increased confidence in the stock's potential.
• Prominent investors like David Tepper and Michael Burry have been actively investing in ELV, signaling trust in its undervaluation and future growth.
• Despite facing challenges like rising Medical Care Ratios and regulatory changes, Elevance Health's strategic actions, such as reducing its Medicare Advantage membership and utilizing its balance sheet, are setting the stage for margin recovery and expansion.

ELV Price Chart

ELV Technical Analysis

ELV News

Why the Market Is Wrong on UnitedHealth

UnitedHealth Group has faced significant market pressure due to rising Medical Care Ratio (MCR) and regulatory shifts, but a deeper analysis suggests these are temporary headwinds. The company is strategically shrinking its Medicare Advantage membership and leveraging its strong balance sheet to absorb costs, positioning itself for future growth and margin recovery. Noted investors like David Tepper and Michael Burry have also aggressively bought the stock, indicating a belief in its undervaluation.

https://www.tradingview.com/news/gurufocus:0c028f05f094b:0-why-the-market-is-wrong-on-unitedhealth/

Baird Adjusts Price Target on Elevance Health to $340 From $297, Maintains Neutral Rating

Baird has adjusted its price target for Elevance Health (ELV) to $340, up from $297, while maintaining a Neutral rating on the stock. This update comes amidst other analyst adjustments, with the company also recently announcing the appointment of Amy Schulman as an independent director effective January 12, 2026. Elevance Health, a leading American health insurance provider, reaffirmed its 2025 earnings guidance at $24.70 per share in a recent SEC filing.

https://www.marketscreener.com/news/baird-adjusts-price-target-on-elevance-health-to-340-from-297-maintains-neutral-rating-ce7d50dbdb88f621

Elevance Health (ELV) Appoints Amy W. Schulman as Independent Director

Elevance Health (ELV) has appointed Amy W. Schulman as an independent director, effective January 12, 2026. She will also join the company's Audit and Finance Committees and is recognized as an "audit committee financial expert." This appointment aims to strengthen the company's governance and oversight capabilities.

https://www.gurufocus.com/news/3244426/elevance-health-elv-appoints-amy-w-schulman-as-independent-director

Elevance Health appoints healthcare executive Amy Schulman to board By Investing.com

Elevance Health announced the appointment of Amy Schulman, a healthcare executive and venture capital leader, to its board of directors, effective January 12, 2026. Schulman will serve on the company's Audit and Finance Committees. This appointment aligns with Elevance Health's board refreshment strategy to ensure diverse and independent leadership.

https://uk.investing.com/news/company-news/elevance-health-appoints-healthcare-executive-amy-schulman-to-board-93CH-4411750

Elevance Health (NYSE: ELV) appoints Amy Schulman to board, joining Audit and Finance panels

Elevance Health (NYSE: ELV) has appointed Amy Schulman, a distinguished healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will bring extensive expertise in healthcare innovation, regulatory strategy, and value creation to the company's Audit and Finance Committees. This appointment aligns with Elevance Health's strategy to enhance its board with diverse, independent, and forward-thinking leadership.

https://www.stocktitan.net/news/ELV/elevance-health-board-welcomes-amy-schulman-as-new-director-uz1u9i0gzd4b.html

Trending Today

Dash ($DASH) Crypto Forecast: Down 6.5% Today

Elevance Health Inc. Price History

22.09.2025 - ELV Stock was down 0.8%

• Despite surpassing earnings estimates, ELV faced a downward trend attributable to Medicare cost pressures, Obamacare plan dynamics, and Medicaid attrition, influencing investor sentiment.
• The Q3 performance, marked by significant Medicare Advantage membership growth and Carelon revenue increase, was overshadowed by Medicaid losses impacting the stock's value.
• Analysts' projections concerning ELV's Q3 earnings did not fully anticipate the challenges stemming from Medicare cost pressures and Medicaid attrition, contributing to the recent bearish market trend.

15.07.2025 - ELV Stock was up 5.0%

• Despite a recent decline in YTD performance, ELV showed a strong bullish movement today, indicating a potential turnaround in investor sentiment.
• The company's cost-cutting measures and focus on commercial growth may have positively impacted the stock price.
• Analyst pessimism and concerns over rising costs could have been overshadowed by the company's efforts to address these issues, leading to the bullish market movement.
• ELV's strategic initiatives to stabilize performance and leverage long-term growth levers seem to have resonated well with investors, driving the stock higher.

17.06.2025 - ELV Stock was down 10.5%

• ELV's Q2 revenue rose by 14.3% year-over-year, exceeding projections. However, the company reduced its FY25 EPS guidance due to increased ACA and Medicaid expenses.
• Anticipated cost escalations and decreased Medicaid enrollments are likely to impact ELV's Q2 earnings.
• Investor apprehension may stem from doubts about the company's capability to efficiently control expenses and sustain profitability in the face of tough market conditions.

17.06.2025 - ELV Stock was down 12.9%

• ELV's Q2 earnings fell short of expectations due to escalating medical expenses, particularly related to Medicaid and ACA.
• Despite a 14.3% increase in Q2 revenue compared to the previous year, the company adjusted its FY25 EPS forecast downwards, sparking worries among investors.
• The market responded unfavorably to the announcement of potential profit challenges arising from higher costs and decreased Medicaid enrollments.
• The convergence of earnings missing estimates, guidance revision, and apprehensions about cost pressures contributed to a significant drop in ELV's stock price today.

31.09.2025 - ELV Stock was down 5.1%

• The surge in implied volatility for Elevance Health stock options indicates increased uncertainty and potential downside risk perceived by investors.
• The heightened options activity could suggest speculation or hedging strategies being implemented by market participants, reflecting a lack of confidence in ELV's short-term outlook.
• The overall bearish movement in ELV's stock price today might be attributed to the escalating concerns and cautious sentiment among investors, as reflected in the options market activity.

18.06.2025 - ELV Stock was down 6.1%

• ELV stock experienced a strong bearish movement today due to a series of negative news and analyst actions.
• The company's Q2 earnings missed estimates, with EPS sliding and facing pressure from rising medical costs, particularly from Medicaid and ACA expenses.
• Despite a 14.3% Y/Y increase in Q2 revenue, ELV's FY25 EPS guidance was cut below consensus, citing higher costs.
• Analyst downgrades and concerns about rising costs and lower Medicaid memberships contributed to the bearish market movement of ELV today.

18.06.2025 - ELV Stock was down 8.4%

• ELV's Q2 earnings fell short of expectations because of escalating medical expenses, mainly from Medicaid and ACA costs.
• Although there was a 14.3% rise in Q2 revenue compared to the previous year, the company reduced its projected FY25 EPS, pointing to increased ACA and Medicaid expenses as the main factors.
• Analysts issued downgrades on Elevance Health, which added to the pessimistic outlook on the stock.
• Concerns about surging costs and declining Medicaid enrollments affecting ELV's profitability in the second quarter led to a negative market response.

03.09.2025 - ELV Stock was up 5.2%

• ELV's bullish movement could be attributed to Cigna expanding coverage to Cleerly's AI cardiovascular imaging solutions.
• The partnership with Cigna is seen as a significant endorsement of ELV's technology, leading to increased investor confidence and driving the stock price higher.
• This development highlights the growing importance of early detection and digital healthcare solutions, positioning ELV as a key player in the evolving healthcare industry.

11.11.2025 - ELV Stock was up 6.0%

• Elevance Health (ELV) has shown a strong bullish movement in the market recently.
• The appointment of Amy W. Schulman as an independent director is being viewed positively, enhancing the company's governance and oversight capabilities.
• Analysts have adjusted the price target for ELV to $340 from $297, maintaining a Neutral rating, indicating increased confidence in the stock's potential.
• Prominent investors like David Tepper and Michael Burry have been actively investing in ELV, signaling trust in its undervaluation and future growth.
• Despite facing challenges like rising Medical Care Ratios and regulatory changes, Elevance Health's strategic actions, such as reducing its Medicare Advantage membership and utilizing its balance sheet, are setting the stage for margin recovery and expansion.

11.11.2025 - ELV Stock was up 6.9%

• Adjusting the price target to $340 from $297 and maintaining a Neutral rating could have instilled confidence in investors, leading to increased buying activity.
• The appointment of Amy W. Schulman as an independent director, known for her expertise in healthcare innovation and governance, may have signaled to the market a strategic move towards strengthening governance and oversight capabilities, positively impacting investor sentiment.
• The reaffirmation of 2025 earnings guidance at $24.70 per share in a recent SEC filing could have provided clarity and reassurance to investors, further supporting the bullish momentum in the stock.
• The focus on board refreshment strategy with diverse and independent leadership aligns with market trends towards corporate governance best practices, potentially attracting more investors to the stock.

11.11.2025 - ELV Stock was up 5.5%

• ELV experienced a strong bullish movement today.
• The appointment of Amy W. Schulman, a distinguished healthcare executive, to the company's board of directors seems to have boosted investor confidence in ELV's governance and strategic direction.
• Analysts' positive outlook on ELV, with a 'Buy' rating and a median price target of $394, further contributed to the bullish sentiment.
• ELV's focus on healthcare innovation and strategic growth initiatives align well with market trends emphasizing technology-driven approaches in the healthcare sector.

21.09.2025 - ELV Stock was up 0.0%

• ELV's bullish movement could be attributed to positive projections for key metrics ahead of its Q3 earnings report.
• Investors may be optimistic about the company's performance in the quarter ended September 2025, leading to increased buying activity.
• The anticipation of strong financial results and key metrics could be driving the bullish sentiment in ELV's stock today.